Abstract | BACKGROUND: DESIGN AND METHODS: RESULTS: According to RIFLE criteria, 137 (68.5%) patients had AKI. Five causes of AKI accounted for 91.4% of cases: hypoperfusion, tumor lysis syndrome, tubular necrosis, nephrotoxic agents, and hemophagocytic lymphohistiocytosis. Half of the AKI patients received renal replacement therapy and 14.6% received suboptimal chemotherapy. AKI was associated with a lower 6-month complete remission rate (39.4% vs. 68.3%, P<0.01) and a higher mortality rate (47.4% vs. 30.2%, P<0.01) than patients without AKI. By multivariate analysis, independent determinants of 6-month complete remission were older age, poor performance status, number of organ dysfunctions, and AKI. CONCLUSION: AKI is common in patients with newly diagnosed high-grade malignancies and is associated with lower complete remission rates and higher mortality.
|
Authors | Emmanuel Canet, Lara Zafrani, Jerome Lambert, Catherine Thieblemont, Lionel Galicier, David Schnell, Emmanuel Raffoux, Etienne Lengline, Sylvie Chevret, Michael Darmon, Elie Azoulay |
Journal | PloS one
(PLoS One)
Vol. 8
Issue 2
Pg. e55870
( 2013)
ISSN: 1932-6203 [Electronic] United States |
PMID | 23457485
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Acute Kidney Injury
(complications, mortality, pathology, therapy)
- Adult
- Antineoplastic Agents
(therapeutic use)
- Female
- Hematologic Neoplasms
(complications, mortality, pathology, therapy)
- Humans
- Kidney
(pathology)
- Male
- Middle Aged
- Multivariate Analysis
- Prospective Studies
- Remission Induction
- Renal Replacement Therapy
- Survival Rate
- Treatment Outcome
|